Q-omics provides the consensus-scored SEPTIN8 profile across patient tissues and cancer cell-line models. SEPTIN8 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SEPTIN8 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SEPTIN8 protein abundance shows 26,713 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, COAD, and PDAC as cancer lineages where SEPTIN8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEPTIN8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEPTIN8 survival associations across molecular data types. SEPTIN8 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEPTIN8 RNA expression–survival associations across cancer types. High SEPTIN8 expression shows unfavorable associations in ACC, MESO, HNSC, STAD and KIRP, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SEPTIN8 RNA expression.
This table summarizes SEPTIN8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SEPTIN8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEPTIN8 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, STAD, BLCA and BRCA. The COAD box plot shows higher SEPTIN8 RNA expression in tumor versus normal tissue (log2 FC = +0.611, t-test p < 0.001).
This table shows molecular features associated with SEPTIN8 in patient tissues and cancer cell lines. In patient samples, SEPTIN8 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SEPTIN8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
